Phytoestrogens limit translation of preclinical results to clinical outcomes

Ask a Nutritionist Series: Impact of phytoestrogens on research, Volume 2

Dietary phytoestrogens exert both estrogen dependent and independent effects and have been shown to have broad effects on research outcomes in rodent models (Table 1). Effects of isoflavones observed in rodents may not translate to clinical outcomes in humans due to differences in total intake and endogenous and microbial metabolism (Figure 1).

**Rodents fed soy containing diets consume higher levels of isoflavones than humans**

Rodents fed soybean meal containing laboratory diets consume higher levels of isoflavones than human populations. Dietary isoflavone level is dependent on the soybean meal inclusion rate and is influenced by soy genetics and growing conditions. Isoflavone levels in rodent diets containing soybean meal can range from approximately 80 – 790 ppm (genistein + daidzein) resulting in an isoflavone intake range of 8 – 118 mg/kg body weight per day (Table 2). This intake range is more than 10 times higher than adult Western populations even when scaled for body surface area (1-6) (Table 2 dark grey columns).

Isoflavone intake levels for infants fed soy formula approach levels consumed by rodents fed diets containing 5 – 10% soybean meal (7), however differences in metabolism and pharmacokinetics of isoflavones likely result in differences in physiological responses to consumed isoflavones.

**Challenge:**
Dietary isoflavones limit translation of preclinical results to clinical outcomes.

**Solution:**
Envigo’s minimal isoflavone Teklad Global Rodent Diets lead to reliable, repeatable research results.

- Isoflavone consumption is higher in rodents fed soybean meal containing lab diets than humans.
- Rodents have higher proportion of circulating unconjugated isoflavones than humans. Unconjugated soy isoflavones have greater activity.
- Rodents are consistent producers of equol, a more physiologically active isoflavone metabolite, while humans are inconsistent equol producers.
- In order to improve translation of rodent results to human outcomes, strong consideration should be given to the avoidance of soybean meal-containing lab animal diets.
Species effects on phase II metabolism results in differences in isoflavone bioactivity

The primary forms of isoflavones consumed by rodents and humans are the glycosides genistin and daidzin. These glycoside forms are poorly absorbed, so once ingested the glycoside moiety is removed via endogenous and microbial β-glucosidases. Upon uptake by the enterocyte and liver the majority of free aglycone forms (genistein and daidzein) undergo conjugation via Phase II metabolism for circulation. Glucuronic acid is the primary Phase II conjugate followed by sulfides. Phase II metabolism of isoflavones affects binding and activation of the intracellular estrogen receptor. Conjugated isoflavones are relatively hydrophilic and it is unclear if these compounds can readily pass through the cell membrane to access the intracellular estrogen receptor. An in vitro study found binding of murine uterine cytosol estrogen receptors was weaker with conjugated isoflavones compared to un conjugated forms. Once activated, the ER receptor translocates into the nucleus, binding DNA to regulate gene expression. Conjugation of isoflavones limits the downstream binding of nuclear receptors in vitro reducing relative potency for the β-ER by ~15 fold for genistein and ~4400 fold for daidzein. Conjugated genistein and daidzein have limited effects on growth of the human MCF-7 cell line compared to aglycone forms. In a transfected cell line with ERα/ERβ ratios mimicking healthy breast cells conjugated isoflavones were found to not be estrogenic.

The ability to activate isoflavones via deconjugation at the tissue level differs between species, with rat breast tissue having a ~30 fold higher deconjugation capacity compared to human breast tissue. Isoflavone conjugation influences physiological effects and conjugation ratios differ between rodent strains and sexes as well as between rodents and humans.

In general, the proportion of circulating unconjugated isoflavones is ranked mice > rats > humans. Compared to C57BL/6 mice and Sprague-Dawley rats, nude mice and the transgenic mouse model Angptl4b6 have higher proportions of unconjugated circulating isoflavones. While sex does not appear to affect conjugation patterns in humans, sex and hormonal changes do affect conjugation patterns in rodent models. Hormone status in Sprague-Dawley rats affected both oral bioavailability of genistein and circulating conjugated isoflavones. The ability to deconjugate isoflavones at the tissue level has also been shown to differ between rodents and human models.

Differences in conjugation patterns between humans and rodents influence isoflavone activity and physiological effects.
**Equol production differs in humans and rodents**

Equol is a metabolite of daidzein that is exclusively produced by bacteria\(^{20-22}\). This metabolite has a greater affinity for the estrogen receptor (ER) and higher biological activity than the parent compound daidzein\(^{20, 23}\). Microbial production of equol can be affected by a number of variables in rodents and humans. Feeding a soy containing diet to conventionally raised rodent results in the production of equol but not in germ-free rats\(^{22}\). While conventional rodents are consistent equol producers when fed soybean meal, equol production varies in humans. Only 25 – 30% of the adult Western population is considered “equol producers” while 50 – 70% of adults in Japan, China and Korea produce equol\(^{20, 23}\). Differences in equol production may be related to differences in nutrient intake and lactase phlorizin hydrolase activity, the enzyme responsible for both the hydrolysis of lactase and deglycosylation of isoflavones\(^{20, 24}\). Differences between rodents and humans in circulating levels of equol can affect the translation of preclinical results to clinical outcomes.

---

**Translated Isoflavone Intakes from Human to Rodents**

<table>
<thead>
<tr>
<th>Population</th>
<th>Isoflavone intake, mg/day</th>
<th>Human isoflavone intake, mg/kg/day</th>
<th>Equivalent rodent intake, mg/kg/day(^{a})</th>
<th>Dietary soybean meal level</th>
<th>Typical dietary isoflavone range(^{b}), ppm</th>
<th>Rodent isoflavone intake(^{c}), mg/kg/day</th>
</tr>
</thead>
<tbody>
<tr>
<td>Western adults</td>
<td>1 - 3(^{(1)})</td>
<td>0.01 - 0.05</td>
<td>0.1 - 0.6</td>
<td>Low</td>
<td>80 - 175</td>
<td>8 - 26</td>
</tr>
<tr>
<td>East Asian adults</td>
<td>15 - 50(^{4-6})</td>
<td>0.2 - 0.8</td>
<td>1.4 - 10.2</td>
<td>Medium</td>
<td>150 - 340</td>
<td>15 - 51</td>
</tr>
<tr>
<td>Infants fed soy milk</td>
<td>20 - 45(^{(7)})</td>
<td>6 - 11</td>
<td>20 - 55</td>
<td>High</td>
<td>350 - 790</td>
<td>35 - 118</td>
</tr>
</tbody>
</table>

**Table 2.** Comparison of consumption of isoflavones in humans and rodents.

---

\(^{a}\) Equivalent Rodent Intake = Human Isoflavone Intake/((animal weight in kg/human weight in kg)\(^{0.33}\))\(^{25}\). Unless provided by the original reference, adult human body weight is assumed to be 60 kg, mouse weight 20 g and feed intake 3 g, rat weigh 150 g and feed intake 15 g.

\(^{b}\) Envigo diets containing low (~5%), medium (~10%) and high (~25%) amounts of soybean meal during the same time period\(^{25}\).

\(^{c}\) Assuming mice weigh 20 g and consume 3 g diet/day and rats weigh 150 g and consume 15 g diet/day.